Malathi Hari
Overview
Explore the profile of Malathi Hari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
206
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yin S, Zeng C, Hari M, Cabral F
Cytoskeleton (Hoboken)
. 2013 Oct;
70(12):849-62.
PMID: 24155014
Many mammalian β-tubulin mutations that confer paclitaxel resistance have been characterized, but little is currently known about the role of α-tubulin mutations in drug resistance. Previous studies using two-dimensional gel...
2.
Yin S, Zeng C, Hari M, Cabral F
Pharm Res
. 2012 Jun;
29(11):2994-3006.
PMID: 22669706
Purpose: Previous research showed that mutations in β1-tubulin are frequently involved in paclitaxel resistance but the question of whether the mutations are restricted by cell-type specific differences remains obscure. Methods:...
3.
Sampath D, Greenberger L, Beyer C, Hari M, Liu H, Baxter M, et al.
Clin Cancer Res
. 2006 Jun;
12(11 Pt 1):3459-69.
PMID: 16740771
Purpose: Because resistance to paclitaxel and docetaxel is frequently observed in the clinic, new anti-microtubule agents have been sought. The aim of this study was to evaluate the efficacy and...
4.
Hari M, Loganzo F, Annable T, Tan X, Musto S, Morilla D, et al.
Mol Cancer Ther
. 2006 Mar;
5(2):270-8.
PMID: 16505100
Resistance to paclitaxel-based therapy is frequently encountered in the clinic. The mechanisms of intrinsic or acquired paclitaxel resistance are not well understood. We sought to characterize the resistance mechanisms that...
5.
Nunes M, Kaplan J, Wooters J, Hari M, Minnick Jr A, May M, et al.
Biochemistry
. 2005 May;
44(18):6844-57.
PMID: 15865430
A synthetic analogue of the tripeptide hemiasterlin, designated HTI-286, depolymerizes microtubules, is a poor substrate for P-glycoprotein, and inhibits the growth of paclitaxel-resistant tumors in xenograft models. Two radiolabeled photoaffinity...
6.
Loganzo F, Hari M, Annable T, Tan X, Morilla D, Musto S, et al.
Mol Cancer Ther
. 2004 Oct;
3(10):1319-27.
PMID: 15486199
HTI-286, a synthetic analogue of hemiasterlin, depolymerizes microtubules and is proposed to bind at the Vinca peptide site in tubulin. It has excellent in vivo antitumor activity in human xenograft...
7.
Hari M, Yang H, Zeng C, Canizales M, Cabral F
Cell Motil Cytoskeleton
. 2003 Aug;
56(1):45-56.
PMID: 12905530
Human brain and testis specific betaIII-tubulin was amplified from a cDNA library, modified to encode a C-terminal hemagglutinin antigen epitope tag, and cloned into a vector that allows tetracycline regulated...
8.
Hari M, Wang Y, Veeraraghavan S, Cabral F
Mol Cancer Ther
. 2003 Jul;
2(7):597-605.
PMID: 12883031
Single-step selections were used to obtain Chinese hamster ovary cell lines resistant to Colcemid and vinblastine. Verapamil was included in the selections to circumvent the isolation of cells with P-glycoprotein-mediated...
9.
Loganzo F, Discafani C, Annable T, Beyer C, Musto S, Hari M, et al.
Cancer Res
. 2003 Apr;
63(8):1838-45.
PMID: 12702571
Hemiasterlin is a natural product derived from marine sponges that, like other structurally diverse peptide-like molecules, binds to the Vinca-peptide site in tubulin, disrupts normal microtubule dynamics, and, at stoichiometric...